| Literature DB >> 32973058 |
Marta M Rey-Rodriguez1, M A Vazquez-Gamez2, Mercè Giner3, Fernando Garrachón-Vallo4, Luis Fernández-López4, Miguel Angel Colmenero4, María-José Montoya-García2.
Abstract
OBJECTIVE: To evaluate the incidence of osteoporotic hip fracture in the Macarena Health Area (Seville). SETTING AND PARTICIPANTS: This was a prospective observational study that collected all osteoporotic hip fractures that occurred between March 2013 and February 2014 at the Clinical Unit of Traumatology and Orthopaedics. All cases collected during the first 6 months of the study were followed for 1 year after the occurrence of the event. OUTCOME MEASURES: We evaluated the incidence of osteoporotic hip fractures in the Macarena Health Area (Seville) from 1 March 2013 to 28 February 2014, and we compared the incidence with that in 2 previous studies carried out with the same methodology in 1994 and 2006. Furthermore, we calculated the morbidity and degree of disability 1 year after the fracture occurred and determined mortality and the associated factors.Entities:
Keywords: bone diseases; geriatric medicine; hip
Mesh:
Year: 2020 PMID: 32973058 PMCID: PMC7517558 DOI: 10.1136/bmjopen-2020-037101
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow diagram of the study design.
Characteristics of the patients with osteoporotic hip fractures in the 2014 study
| Characteristic | Women | Men |
| Age (years), mean (SD) | 82.7 (7.2) | 81.2 (8.4) |
| Body mass index (kg/m2), mean (SD) | 27.6 (5.6) | 26.0 (4.2) |
| Comorbidities* n (%) | ||
| Hypertension | 209 (77.4) | 64 (71.9) |
| Cardiovascular disease | 147 (54.4) | 58 (65.2) |
| Osteoarthritis | 138 (51.1)† | 22 (24.7)† |
| Dyslipidaemia | 95 (35.2) | 30 (33.7) |
| Dementia | 92 (34.1) | 25 (28.1) |
| Diabetes | 86 (31.9) | 28 (31.5) |
| Hypothyroidism | 35 (13.0)† | 4 (4.5)† |
| Renal failure | 23 (8.5) | 13 (14.6) |
| Drug treatment* n (%) | ||
| Antihypertensive agents | 199 (73.7) | 64 (71.9) |
| Drugs acting on the CNS | 189 (70.0)† | 51 (57.3)† |
| Proton pump inhibitors | 128 (47.4) | 52 (58.4) |
| Antiplatelet agents | 107 (39.6) | 42 (47.2) |
| Statins | 69 (25.6) | 23 (25.8) |
| Anticoagulants | 56 (20.7) | 11 (12.4) |
| Calcium + vitamin D | 36 (13.3) | 6 (6.7) |
| Antiresorptive agents | 26 (9.6) | 3 (3.4) |
| History of fracture | 121 (44.7) | 33 (36.9) |
| History of falls in the previous year | 239 (88.4) | 75 (80.3) |
| Circumstances leading to falls | 190 (70.3) | 61 (67.1) |
| Risk of hip fracture ≥3% according to FRAX | 241 (89.4) | 60 (67.1) |
| Type of fracture, n (%) | ||
| Extracapsular | 165 (61.1) | 45 (50.6) |
| Intracapsular | 105 (38.9) | 44 (49.4) |
| Time to surgery (days), mean (SD) | 5.0 (5.3) | 5.5 (7.8) |
| Hospital stay (days), mean (SD) | 10.9 (4.8) | 11.2 (6.0) |
*Had a frequency ≥10% for at least one sex (for this selection, the figures have been rounded to the nearest whole number).
†P<0.05.
CNS, central nervous system.
Figure 2(A) Incidence of osteoporotic hip fractures in men by age in the three studies analysed. (B) Incidence of osteoporotic hip fractures in women by age in the three studies analysed.
Evolution of in-hospital mortality in patients with osteoporotic hip fracture
| 1994 | 2006 | 2014 | |
| Women | 2.3 | 9.0 | 4.8 |
| Men | 6.5 | 17.0 | 9.0 |
| Total | 3.1 | 10.8 | 5.8 |
All figures are the percentages of patients.
Factors associated with in-hospital mortality and mortality after the first year in patients with osteoporotic hip fracture
| Variable | P value | OR | 95% CI |
| In-hospital mortality | |||
| Age (≤85 years) | 0.015 | 3.44 | 1.28 to 9.28 |
| Renal failure (Creatinine ≥1.2 mg/dL) | 0.011 | 3.31 | 1.31 to 8.37 |
| Mortality after the first year | |||
| Body mass index (≥25 mg/m2) | 0.006 | 3.48 | 1.44 to 8.43 |
| Renal failure (creatinine ≥1.2 mg/dL) | 0.011 | 5.07 | 1.45 to 17.68 |
| Plasma proteins (≥6 g/dL) | 0.005 | 3.88 | 1.51 to 9.93 |
Figure 3Evolution of autonomy and dependence 1 year after osteoporotic hip fracture.